Gilead, US square off in billion-dollar HIV drug patent trial

Argentina Noticias Noticias

Gilead, US square off in billion-dollar HIV drug patent trial
Argentina Últimas Noticias,Argentina Titulares
  • 📰 Reuters
  • ⏱ Reading Time:
  • 34 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 97%

Gilead Sciences Inc is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.

is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.

Jury selection starts on Tuesday in the case, which marks one of the first times the U.S. government has sued a drug maker to enforce its patent rights. The government received four patents for HIV prevention drug regimens that CDC researchers invented. Its lawsuit claims the patents also cover Gilead's pre-exposure prophylaxis drug regimen for lowering HIV infection risk.

Gilead made more than $2 billion last year from worldwide sales of Truvada and Descovy, according to a company report. Descovy, which earned Gilead over $1.8 billion last year, is its fourth-best selling drug behind the HIV drugs Biktarvy and Genvoya and COVID-19 treatment Veklury.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

Reuters /  🏆 2. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Trial set for drugmaker accused of profiting from government patentsTrial set for drugmaker accused of profiting from government patentsThe U.S. government claims Gilead Sciences has made billions of dollars by capitalizing on an anti-HIV regimen patented by the CDC, while the drugmaker argues the patents are invalid.
Leer más »

Mace rejects criticism for wearing a tux to White House dinner: ‘This ain’t Gilead’Mace rejects criticism for wearing a tux to White House dinner: ‘This ain’t Gilead’Rep. Nancy Mace wore a tuxedo to the White House Correspondents' Dinner and is firing back at critics: 'They go straight for your appearance.'
Leer más »

Uber Technologies Inc Stock Price Today | NYSE UBER Live Ticker - Investing.comUber Technologies Inc Stock Price Today | NYSE UBER Live Ticker - Investing.comView today's Uber Technologies Inc stock price and latest UBER news and analysis. Create real-time notifications to follow any changes in the live stock price.
Leer más »

Disinformation Inc: House GOP steps up 'censorship' inquiry into Blinken's State DepartmentDisinformation Inc: House GOP steps up 'censorship' inquiry into Blinken's State DepartmentEXCLUSIVE — House Republicans are expanding the scope of their investigation into the Biden administration's alleged ties to 'censorship' and 'disinformation' tracking through a new demand for a trove of records from the State Department.
Leer más »

Fast Five Quiz: Antiretroviral Therapy in HIV -- When to Switch?Fast Five Quiz: Antiretroviral Therapy in HIV -- When to Switch?What do you know about ART switching? Test your knowledge with this quick quiz. MedEd HIV
Leer más »

Uganda lawmakers amend controversial anti-gay law but death penalty for HIV positive sex remains | CNNUganda lawmakers amend controversial anti-gay law but death penalty for HIV positive sex remains | CNNUganda's parliament has passed an amended version of the controversial Anti-Homosexuality Bill 2023 on Tuesday.
Leer más »



Render Time: 2025-04-24 13:35:37